Gene editing, particularly CRISPR technology, offers the potential to eradicate HIV by making accurate edits at a cellular level, with companies like Excision BioTherapeutics leading clinical trials.
Antiretroviral drugs, although effective in managing HIV, pose limitations such as the need for lifelong consumption, accessibility issues, side effects, and the inability to completely eradicate the virus.
Balancing investments between finding a cure for HIV through gene editing and focusing on prevention, diagnoses, and treatment remains a crucial consideration for public and private sectors.
Collection
[
|
...
]